Table 5.
Drug likeness characteristics of synthesized (E)-2-(3-(substitutedstyryl)-5-(substitutedphenyl)-4,5-dihydropyrazol-1-yl)benzo[d]thiazole derivatives
| Comp | miLog Pa | Log Sb (mol/L) |
TPSAc (Å2) |
MWd | nONe | nOHNHf | nvoilatiog | nroth |
|---|---|---|---|---|---|---|---|---|
| Z1 | 4.01 | − 7.13 | 27.97 | 454.43 | 3 | 0 | 0 | 4 |
| Z2 | 4.88 | − 7.13 | 28.49 | 450.39 | 3 | 0 | 0 | 4 |
| Z3 | 4.44 | − 6.582 | 120.14 | 471.50 | 9 | 0 | 0 | 6 |
| Z4 | 6.49 | − 6.582 | 120.14 | 471.50 | 9 | 0 | 1 | 6 |
| Z5 | 6.21 | − 6.582 | 120.14 | 471.50 | 9 | 0 | 1 | 6 |
| Z6 | 4.65 | − 7.134 | 28.49 | 450.39 | 3 | 0 | 0 | 4 |
| Z7 | 4.57 | − 5.07 | 68.95 | 413.50 | 5 | 2 | 0 | 4 |
| Z8 | 5.61 | − 5.07 | 68.95 | 413.50 | 5 | 2 | 1 | 4 |
| Z9 | 4.18 | − 7.33 | 28.49 | 539.30 | 3 | 0 | 1 | 4 |
| Z10 | 7.47 | − 6.35 | 28.49 | 409.56 | 3 | 0 | 1 | 4 |
| Z11 | 6.69 | − 5.698 | 46.96 | 441.56 | 5 | 0 | 1 | 6 |
| Z12 | 6.57 | − 5.662 | 28.49 | 381.50 | 3 | 0 | 1 | 4 |
| Z13 | 3.90 | − 6.29 | 28.49 | 417.48 | 3 | 0 | 0 | 4 |
| Z14 | 4.43 | − 5.698 | 46.96 | 441.56 | 5 | 0 | 1 | 6 |
| Z15 | 6.41 | − 5.698 | 46.96 | 441.56 | 5 | 0 | 1 | 6 |
| Z16 | 8.13 | − 7.33 | 28.49 | 539.30 | 3 | 0 | 2 | 4 |
| Z17 | 8.65 | − 8.606 | 28.49 | 519.28 | 3 | 0 | 2 | 4 |
| Z18 | 8.65 | − 8.606 | 28.49 | 519.28 | 3 | 0 | 2 | 4 |
| Z19 | 6.48 | − 5.734 | 65.43 | 501.61 | 7 | 0 | 2 | 8 |
| Z20 | 5.83 | − 5.77 | 83.90 | 561.66 | 9 | 0 | 2 | 10 |
amiLog P Logarithm of partition coefficient between n-octanol and water
bLogS Solublity
cTPSA Topological polar surface area
dMW Molecular weight
enON Number of hydrogen bond acceptor
fnOHNH Number of hydrogen bond donor
gnvoilations Number of violations
hnrot Number of rotatable bonds